Antibody-Mediated Retinopathies in Canine Patients: Mechanism, Diagnosis, and Treatment Modalities

Veterinary Clinics of North America - Small Animal Practice

Volumn 38, Issue 2, 2008, Pages 361-387

  Grozdanic, Sinisa D ^a   Harper, Matthew M ^a   Kecova, Helga ^a  

^a IOWA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT; AUTOANTIBODY; DOXYCYCLINE; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; PREDNISONE; STEROID;

BLINDNESS; CLINICAL FEATURE; CLINICAL PROTOCOL; COLORIMETRY; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DOG DISEASE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG RESPONSE; DRUG SAFETY; EARLY DIAGNOSIS; ELECTRORETINOGRAPHY; IMMUNE MEDIATED RETINITIS; IMMUNOPATHOLOGY; NONHUMAN; OPHTHALMOSCOPY; OPTICAL COHERENCE TOMOGRAPHY; PATHOGENESIS; PHOTOSTIMULATION; PLASMAPHERESIS; PUPIL REFLEX; RETINOPATHY; REVIEW; SUDDEN ACQUIRED RETINAL DEGENERATION SYNDROME; ANIMAL; ANIMAL DISEASE; DIFFERENTIAL DIAGNOSIS; DOG; IMMUNOLOGY; KIRISAWA UVEITIS; PROGNOSIS; RETINA DISEASE; RETINITIS; VISUAL ACUITY;

ANIMALS; DIAGNOSIS, DIFFERENTIAL; DOG DISEASES; DOGS; PROGNOSIS; RETINAL DISEASES; RETINAL NECROSIS SYNDROME, ACUTE; RETINITIS; VISUAL ACUITY;

EID: 43149092488     PISSN: 01955616     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cvsm.2007.12.003     Document Type: Review

References (62)

1. Vainisi SJ, Schmidt GM, West CS. Metabolic toxic retinopathy-preliminary report. In: Proceedings 14th Annu Meet Am Coll Vet Ophthalmol; 1983.
2. Vainisi S.J., Font R.L., and Anderson R. Idiopathic photoreceptor cell degeneration in dogs. [abstract]. Invest Ophthalmol Vis Sci 26 Suppl 3 (1985)
3. Abrams K.L., Gareen I.F., and Marchand K.N. Factors associated with canine sudden acquired retinal degeneration syndrome (SARDS)-350 cases. [abstract]. Vet Ophthalmol 4 4 (2001) 289-300
4. Gilmour M.A. Clinical follow-up on 15 dogs with sudden acquired retinal degeneration syndrome. Vet Ophthalmol 7 6 (2004) 437-453
5. Carter R.T., Bentley E., Oliver J.W., et al. Elevations in adrenal sex hormones in canine sudden acquired retinal degeneration syndrome (SARDS). Vet Ophthalmol 7 6 (2004) 437-453
6. Grozdanic S.D., Matic M., Sakaguchi D.S., et al. Evaluation of retinal status using chromatic pupil light reflex activity in healthy and diseased canine eyes. Invest Ophthalmol Vis Sci 48 (2007) 5178-5183
7. Grozdanic SD, Harper MH, Boll AE, et al. Antobody-mediated retinopathy-new mechanisms and treatment strategies. Invest Opthalmol Vis Sci, submitted for publication.
8. Abrams KL, Dreyer EB. Excitotoxicity in canine sudden acquired retinal degeneration. Proceedings of the Association for Research in Vision and Ophthalmology 1993;34:3297.
9. Bellhorn R.W., Murphy C.J., and Thirkill C.E. Anti-retinal immunoglobulins in canine ocular diseases. Semin Vet Med Surg (Small Anim) 3 (1988) 28-32
10. Keller R.L., Kania S.A., Hendrix D.V., et al. Evaluation of canine serum for the presence of antiretinal autoantibodies in sudden acquired retinal degeneration syndrome. Vet Ophthalmol 9 (2006) 195-200
11. Gilmour M.A., Cardenas M.R., Blaik M.A., et al. Evaluation of a comparative pathogenesis between cancer-associated retinopathy in humans and sudden acquired retinal degeneration syndrome in dogs via diagnostic imaging and western blot analysis. Am J Vet Res 67 (2006) 877-881
12. Miller P.E., Galbreath E.J., Kehren J.C., et al. Photoreceptor cell death by apoptosis in dogs with sudden acquired retinal degeneration syndrome. Am J Vet Res 59 (1998) 149-152
13. Van Gelder R.N. Nonvisual ocular photoreception in the mammal. Methods Enzymol 393 (2005) 746-755
14. Ruby N.F., Brennan T.J., Xie X., et al. Role of melanopsin in circadian responses to light. Science 298 (2002) 2211-2213
15. Hanifin J.P., and Brainard G.C. Photoreception for circadian, neuroendocrine, and neurobehavioral regulation. J Physiol Anthropol 26 (2007) 87-94
16. Klingele T.G., Burde R.M., Rappazzo J.A., et al. Paraneoplastic retinopathy. J Clin Neuroophthalmol 4 (1984) 239-245
17. Guy J., and Aptsiauri N. Treatment of paraneoplastic visual loss with intravenous immunoglobulin: report of 3 cases. Arch Ophthalmol 117 (1999) 471-477
18. Keltner J.L., Thirkill C.E., Tyler N.K., et al. Management and monitoring of cancer-associated retinopathy. Arch Ophthalmol 110 (1992) 48-53
19. Keltner J.L., Thirkill C.E., and Yip P.T. Clinical and immunologic characteristics of melanoma-associated retinopathy syndrome: eleven new cases and a review of 51 previously published cases. J Neuroophthalmol 21 (2001) 173-187
20. Murphy M.A., Thirkill C.E., and Hart Jr. W.M. Paraneoplastic retinopathy: a novel autoantibody reaction associated with small-cell lung carcinoma. J Neuroophthalmol 17 (1997) 77-83
21. Kaneko Y., Nimmerjahn F., and Ravetch J.V. Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313 (2006) 670-673
22. Nimmerjahn F., and Ravetch J.V. The antiinflammatory activity of IgG: the intravenous IgG paradox. J Exp Med 204 (2007) 11-15
23. Kempf C., Stucki M., and Boschetti N. Pathogen inactivation and removal procedures used in the production of intravenous immunoglobulins. Biologicals 35 (2007) 35-42
24. Boschetti N., Stucki M., Spath P.J., et al. Virus safety of intravenous immunoglobulin: future challenges. Clin Rev Allergy Immunol 29 (2005) 333-344
25. Kaneko Y., Nimmerjahn F., Madaio M.P., et al. Pathology and protection in nephrotoxic nephritis is determined by selective engagement of specific Fc receptors. J Exp Med 203 (2006) 789-797
26. Samuelsson A., Towers T.L., and Ravetch J.V. Anti-inflammatory activity of IVIG mediated through the inhibitory Fc receptor. Science 291 (2001) 484-486
27. Vaccaro C., Zhou J., Ober R.J., et al. Engineering the Fc region of immunoglobulin G to modulate in vivo antibody levels. Nat Biotechnol 23 (2005) 1283-1288
28. Bianco D., Armstrong P.J., and Washabau R.J. Treatment of severe immune-mediated thrombocytopenia with human IV immunoglobulin in 5 dogs. J Vet Intern Med 21 (2007) 694-699
29. Nuttall T.J., and Malham T. Successful intravenous human immunoglobulin treatment of drug-induced Stevens-Johnson syndrome in a dog. J Small Anim Pract 45 (2004) 357-361
30. Rahilly L.J., Keating J.H., and O'Toole T.E. The use of intravenous human immunoglobulin in treatment of severe pemphigus foliaceus in a dog. J Vet Intern Med 20 (2006) 1483-1486
31. Trotman T.K., Phillips H., Fordyce H., et al. Treatment of severe adverse cutaneous drug reactions with human intravenous immunoglobulin in two dogs. J Am Anim Hosp Assoc 42 (2006) 312-320
32. Schiavotto C., Ruggeri M., and Rodeghiero F. Adverse reactions after high-dose intravenous immunoglobulin: incidence in 83 patients treated for idiopathic thrombocytopenic purpura (ITP) and review of the literature. Haematologica 78 (1993) 35-40
33. Stenton S.B., Dalen D., and Wilbur K. Myocardial infarction associated with intravenous immune globulin. Ann Pharmacother 39 (2005) 2114-2118
34. Orbach H., Tishler M., and Shoenfeld Y. Intravenous immunoglobulin and the kidney-a two-edged sword. Semin Arthritis Rheum 34 (2004) 593-601
35. Jolles S., Sewell W.A., and Leighton C. Drug-induced aseptic meningitis: diagnosis and management. Drug Saf 22 (2000) 215-226
36. Gaines A.R. Acute onset hemoglobinemia and/or hemoglobinuria and sequelae following Rh(o)(D) immune globulin intravenous administration in immune thrombocytopenic purpura patients. Blood 95 (2000) 2523-2529
37. Adamus G, Ren G, Weleber RG. Autoantibodies against retinal proteins in paraneoplastic and autoimmune retinopathy. Available at: http://www.biomedcentral.com/1471-2415/4/5.
38. Thirkill C.E., FitzGerald P., Sergott R.C., et al. Cancer-associated retinopathy (CAR syndrome) with antibodies reacting with retinal, optic-nerve, and cancer cells. N Engl J Med 321 (1989) 1589-1594
39. Thirkill C.E. Experimental, cancer-induced retinopathy. Ocul Immunol Inflamm 5 (1997) 55-65
40. Patel N., Ohbayashi M., Nugent A.K., et al. Circulating anti-retinal antibodies as immune markers in age-related macular degeneration. Immunology 115 (2005) 422-430
41. Cherepanoff S., Mitchell P., Wang J.J., et al. Retinal autoantibody profile in early age-related macular degeneration: preliminary findings from the Blue Mountains Eye Study. Clin Experiment Ophthalmol 34 (2006) 590-595
42. Umeda S., Suzuki M.T., Okamoto H., et al. Molecular composition of drusen and possible involvement of anti-retinal autoimmunity in two different forms of macular degeneration in cynomolgus monkey (Macaca fascicularis). FASEB J 19 (2005) 1683-1685
43. Heckenlively J.R., Aptsiauri N., Nusinowitz S., et al. Investigations of antiretinal antibodies in pigmentary retinopathy and other retinal degenerations. Trans Am Ophthalmol Soc 94 (1996) 179-200 [discussion: 200-6]
44. Heckenlively J.R., Jordan B.L., and Aptsiauri N. Association of antiretinal antibodies and cystoid macular edema in patients with retinitis pigmentosa. Am J Ophthalmol 127 (1999) 565-573
45. Heckenlively J.R., Solish A.M., Chant S.M., et al. Autoimmunity in hereditary retinal degenerations. II. Clinical studies: antiretinal antibodies and fluorescein angiogram findings. Br J Ophthalmol 69 (1985) 758-764
46. Romano C., Barrett D.A., Li Z., et al. Anti-rhodopsin antibodies in sera from patients with normal-pressure glaucoma. Invest Ophthalmol Vis Sci 36 (1995) 1968-1975
47. Tezel G., Edward D.P., and Wax M.B. Serum autoantibodies to optic nerve head glycosaminoglycans in patients with glaucoma. Arch Ophthalmol 117 (1999) 917-924
48. Hooks J.J., Tso M.O., and Detrick B. Retinopathies associated with antiretinal antibodies. Clin Diagn Lab Immunol 8 (2001) 853-858
49. Adamus G., Aptsiauri N., Guy J., et al. The occurrence of serum autoantibodies against enolase in cancer-associated retinopathy. Clin Immunol Immunopathol 78 (1996) 120-129
50. Adamus G., Amundson D., MacKay C., et al. Long-term persistence of antirecoverin antibodies in endometrial cancer-associated retinopathy. Arch Ophthalmol 116 (1998) 251-253
51. Adamus G., Guy J., Schmied J.L., et al. Role of anti-recoverin autoantibodies in cancer-associated retinopathy. Invest Ophthalmol Vis Sci 34 (1993) 2626-2633
52. Thirkill C.E., Keltner J.L., Tyler N.K., et al. Antibody reactions with retina and cancer-associated antigens in 10 patients with cancer-associated retinopathy. Arch Ophthalmol 111 (1993) 931-937
53. Thirkill C.E., Roth A.M., and Keltner J.L. Cancer-associated retinopathy. Arch Ophthalmol 105 (1987) 372-375
54. Thirkill C.E., Tait R.C., Tyler N.K., et al. The cancer-associated retinopathy antigen is a recoverin-like protein. Invest Ophthalmol Vis Sci 33 (1992) 2768-2772
55. Weleber R.G., Watzke R.C., Shults W.T., et al. Clinical and electrophysiologic characterization of paraneoplastic and autoimmune retinopathies associated with antienolase antibodies. Am J Ophthalmol 139 (2005) 780-794
56. Heckenlively J.R., Fawzi A.A., Oversier J., et al. Autoimmune retinopathy: patients with antirecoverin immunoreactivity and panretinal degeneration. Arch Ophthalmol 118 (2000) 1525-1533
57. Mizener J.B., Kimura A.E., Adamus G., et al. Autoimmune retinopathy in the absence of cancer. Am J Ophthalmol 123 (1997) 607-618
58. Adamus G. Autoantibody-induced apoptosis as a possible mechanism of autoimmune retinopathy. Autoimmun Rev 2 (2003) 63-68
59. Shiraga S., and Adamus G. Mechanism of CAR syndrome: anti-recoverin antibodies are the inducers of retinal cell apoptotic death via the caspase 9- and caspase 3-dependent pathway. J Neuroimmunol 132 (2002) 72-82
60. Adamus G., Machnicki M., Elerding H., et al. Antibodies to recoverin induce apoptosis of photoreceptor and bipolar cells in vivo. J Autoimmun 11 (1998) 523-533
61. Magrys A., Anekonda T., Ren G., et al. The role of anti-alpha-enolase autoantibodies in pathogenicity of autoimmune-mediated retinopathy. J Clin Immunol 27 (2007) 181-192
62. Maeda T., Maeda A., Maruyama I., et al. Mechanisms of photoreceptor cell death in cancer-associated retinopathy. Invest Ophthalmol Vis Sci 42 (2001) 705-712